AU2019204739A1 - Hepatoprotective Composition Comprising Cabbage Extract - Google Patents
Hepatoprotective Composition Comprising Cabbage Extract Download PDFInfo
- Publication number
- AU2019204739A1 AU2019204739A1 AU2019204739A AU2019204739A AU2019204739A1 AU 2019204739 A1 AU2019204739 A1 AU 2019204739A1 AU 2019204739 A AU2019204739 A AU 2019204739A AU 2019204739 A AU2019204739 A AU 2019204739A AU 2019204739 A1 AU2019204739 A1 AU 2019204739A1
- Authority
- AU
- Australia
- Prior art keywords
- cabbage
- liver
- extract
- cabbage extract
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 240000007124 Brassica oleracea Species 0.000 title claims abstract description 61
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 title claims abstract description 61
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 title claims abstract description 61
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 title claims abstract description 61
- 239000000284 extract Substances 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 230000002443 hepatoprotective effect Effects 0.000 title abstract description 11
- 210000004185 liver Anatomy 0.000 claims abstract description 18
- 208000019423 liver disease Diseases 0.000 claims abstract description 15
- 230000003908 liver function Effects 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 238000000605 extraction Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 235000013402 health food Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 2
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 2
- 206010072268 Drug-induced liver injury Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 231100000354 acute hepatitis Toxicity 0.000 claims description 2
- 231100000594 drug induced liver disease Toxicity 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 235000013305 food Nutrition 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000006872 improvement Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 231100000956 nontoxicity Toxicity 0.000 abstract description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 18
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 10
- 206010067125 Liver injury Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 5
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 231100000753 hepatic injury Toxicity 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 206010019851 Hepatotoxicity Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000027700 hepatic dysfunction Diseases 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 230000007686 hepatotoxicity Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 231100000439 acute liver injury Toxicity 0.000 description 2
- 238000003763 carbonization Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 244000161286 Allium victorialis Species 0.000 description 1
- 235000011644 Allium victorialis Nutrition 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010012225 Delirium tremens Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 244000010000 Hovenia dulcis Species 0.000 description 1
- 235000008584 Hovenia dulcis Nutrition 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003168 generic drug Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000012464 large buffer Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940072651 tylenol Drugs 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a hepatoprotective composition which may be used for the prevention or treatment 5 of liver disease and the improvement of liver function due to its hepatoprotective effect and, at the same time, may be used safely as a food material due to its non-toxicity. More specifically, the present invention relates to a hepatoprotective composition for preventing or treating liver 10 disease and improving liver function, which comprises a cabbage extract as an active ingredient.
Description
Hepatoprotective Composition Comprising Cabbage Extract
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to a hepatoprotective composition which may be used for the prevention or treatment of liver disease and the improvement of liver function due to its hepatoprotective effect and, at the same time, can be used safely as a food material due to its non-toxicity.
Description of the Prior Art
The liver is one of the important organs of the human body, which is responsible for body's metabolism which appropriately changes ingested foods into nutrients required by various tissues and processes waste products remaining after use in tissues. Specifically, the liver secretes bile, a digestive fluid, metabolizes proteins, carbohydrates and fats, stores glycogen, fat-soluble vitamins, and other substances, synthesizes blood-clotting factors, removes wastes and toxins from the blood, regulates blood volume, and destroys old red blood cells.
Various factors, including mental stress, excessive intake of fatty food or alcohol, viral infection, drugs or smoking, exposure to harmful substances such as pollutants, and malnutrition, may cause hepatic dysfunction. In addition, hepatic dysfunction interferes with body's defense and detoxification mechanisms, causing abnormalities in the immune system and causing other diseases. Hepatic dysfunction causes various symptoms such as weakness, hypotension, frequent contusion and hemorrhage, delirium tremens, emotional dullness, electroencephalographic changes, and intraabdominal fluid accumulation.
Acetaminophen (APAP) , a major component of Tylenol, is a generic drug used worldwide for the treatment of fever and pain. It is relatively safe when used at therapeutic concentrations. However, when an excessive amount of APAP is ingested it may cause side effects such as hepatic necrosis, neurotoxin and cirrhosis, and can lead to death in severe cases. Recently, it has been reported that when an excessive amount of APAP is administered to a living body, it enters a large amount of leukocytes, causing acute inflammation. In other words, proinflammatory cytokines, such as interferon-y (IFN-γ), tumor necrosis factor-a (TNF-α), interleukin-1 and IL6, which are well-known cytokines that cause inflammatory responses, are produced in large amounts within 10 hours and accelerate inflammatory responses. Furthermore, inflammatory mediators, such as cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) , are induced by APAP and cause fatal damage to the living body. It has been reported that patients with liver diseases caused by APAP reach about 10% and the toxicity of APAP is more serious in children than adults and more serious in alcohol eaters than non-alcohol eaters. NAC (Nacetylcysteine) is used for the treatment of hepatotoxicity caused by APAP, but it has been reported that NAC is difficult to administer orally due to its very unpleasant odor and taste and the administration of NAC by intravenous injection can cause anaphylactic shock.
In order to diagnose various liver-related diseases, it is necessary to comprehensively perform several biochemical tests. Several test items for this purpose are collectively referred to as liver function tests. Major test items include AST (aspartate aminotransferase), ALT (alanine aminotransferase), ALP (alkaline phosphatase), GGT (gamma-glutamyltransferase), and bilirubin. In addition to these test items, items such as total protein, albumin, LDH (lactate dehydrogenase), ammonia and the like may also be tested. Among them, AST (GOT) and ALT (GPT) are enzymes present in hepatocytes and are released into the blood mainly when hepatocytes are damaged. Thus, blood AST and ALT levels can be used as markers of liver damage. In the early stages of acute hepatocyte injury, the level of AST which is present at a higher concentration in hepatocytes increases compared than the level of ALT, but after 24 to 48 hours and in chronic hepatocyte injury, the level of ALT with a longer halflife generally further increases. In alcoholic hepatitis, AST further increases.
Meanwhile, since the liver is an organ having a large buffer capacity, liver disease symptoms generally do not appear in the initial stage of the disease, and since the amount of pain-feeling nerves in the liver is small, liver disease symptoms are generally found after the disease has worsened considerably. Liver cirrhosis or liver cancer is the last stage to which various liver diseases commonly lead when progressing to a chronic stage. The liver is an organ whose initial care is very important. Accordingly, studies have been conducted to provide hepatoprotective compositions comprising natural substances that can be used safely, and examples thereof include Korean Patent No. 10-0633851 (Composition comprising the extract of heat-treated Allium victorialis L. var. platyphyllum for treating or preventing of liver disease or liver protection) and Korean Patent No. 10-1106499(Food composition with hepatoprotective effect containing the peduncle extracts of Hovenia dulcis Thunb).
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a pharmaceutical composition and a functional health food composition, which have a beneficial effect on the human body and which can be used safely for a long period of time without adverse side effects and also have excellent effects of protecting liver and improving liver function.
To achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating liver disease, comprising a cabbage extract as an active ingredient.
The cabbage extract of the present invention does not show cytotoxicity, and thus can be used safely. In an experiment performed on an animal model with liver injury induced by a drug (APAP), it could be seen that the cabbage extract exhibited the effects of protecting liver and improving liver function by effectively reducing AST and ALT which are liver injury markers, indicating that the cabbage extract is effective as a pharmaceutical composition for preventing or treating liver disease.
In particular, the cabbage extract was effective in treating inflammation of the liver by reducing the expression of the inflammatory mediators 1NOS and COX-2 and the proinflammatory cytokine IL-Ιβ, which are involved in acute inflammatory reactions accompanying liver injury.
In the present invention, an extract of cabbage heattreated at a temperature of 100 to 150°C had a better liver function-improving effect or anti-inflammatory effect than an extract of raw cabbage. A preliminary experiment showed that as the heat treatment temperature increased, the effect of the extract was better, but if the heat treatment temperature was excessively high, carbonization could occur. The heat treatment time is preferably 10 minutes to 12 hours in view of the size of a sample or the heat treatment temperature. It is natural that as the sample size increases and the heat treatment temperature decreases, the heat treatment time increases .
In an example of the present invention, the cabbage extract was more effective against AST known to be more highly expressed in cells in acute liver injury. Accordingly, the pharmaceutical composition of the present invention is more preferably used for the prevention or treatment of acute liver diseases. Examples of these acute liver diseases include, but are not limited to, drug-induced liver disease, alcoholic liver disease, acute hepatitis, and fatty liver.
The cabbage extract may be prepared by water or organic solvent extraction and/or fractionation of raw cabbage, dried cabbage, frozen cabbage or heat-treated cabbage. For efficient extraction, cabbage is more preferably extracted after it is cut finely, crushed or milled. Extraction may be performed using any of extraction methods that are used for extraction of natural substances in the art. For example, extraction may be performed either by juice extraction without using any solvent or by a cold extraction, heat extraction or ultrasonic extraction method that uses a solvent, but is not limited thereto. When extraction is performed using a solvent, the solvent is preferably water, a Cl to C4 alcohol, or a mixture thereof. In addition, in order to further concentrate the active ingredient having effects on liver protection and liver function improvement, the extract may also be fractionated. An extract obtained by juice extraction or an extraction method that uses a solvent may be used without further processing or be used after concentration or drying. It is a matter of course that a conventional drying method, such as spray drying, thermal drying or freeze drying, may be used.
For use as a Hepatoprotective pharmaceutical products, the composition of the present invention may be prepared by a known method in the pharmaceutical field and used alone or in combination with a carrier, a forming agent, a diluent, etc. The composition of the present invention may be formulated into an oral or parenteral preparation and used as a preventive and curative agent against liver diseases. The dosage of active ingredients according to the present invention may be determined appropriately depending on the drug absorption of the active ingredients, dosage form, the patient's age, gender and condition, and the severity of the disease. The administration may be performed once or multiple times a day. The general dosage is 0.001 mg/kg-day to 10 g/kg-day. The composition of the present invention can be used safely without toxicity or side effects, even in the case of long-term administration for the purpose of prevention.
The present invention also provides a functional health food composition for protecting liver and improving liver function, comprising a cabbage extract as an active ingredient. The composition of the present invention may also be useful as a composition for relieving hangover. As in the pharmaceutical composition, it is more preferable to use an extract of cabbage heat-treated at 100 to 150 °C. The details of the cabbage
| extract are as described | above | with | respect to | the |
| pharmaceutical composition. | ||||
| The extract of cabbage | may be | added | preferably in | an |
| amount of 0.01 to 100 wt.% | to the | food | composition of | the |
present invention. The effective dose of the health food composition of the present invention can be used in accordance with the effective dose of the pharmaceutical composition. However, in the case of long-term ingestion for the purpose of health and hygiene or for health care purposes of controlling health, the effective dose may be lower than the lower limit of the above-described range. Since the active ingredient shows no problem in terms of safety, it may also be used in an amount larger than the upper limit of the above-described range. The functional health food of the present invention includes any formulation like tablets, capsules, pills, liquid, etc. The examples of the food to which the composition of the present invention can be added may include any kind of foods, beverages, gums, teas, vitamin complexes, functional health foods, and so forth.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a graph showing the results of evaluating the cytotoxicity of a cabbage extract.
FIG. 2 is a graph showing the results of evaluating the liver function improving activity (ALT) of a cabbage extract.
FIG. 3 is a graph showing the results of evaluating the liver function improving activity (AST) of a cabbage extract.
FIG. 4 shows Η & E staining images of liver tissue used to evaluate the liver function improving effect of a cabbage extract.
FIG. 5 is a graph showing the results of evaluating the anti-inflammatory effect of a cabbage extract.
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, the present invention will be described in detail with reference to the following examples, which are given for the illustrations of the present invention only and not construed to limit the scope of the present invention. The examples of the present invention are subjected to various changes and modification and provided for those skilled in the art to understand the prevent invention more completely.
Examples
Example 1: Preparation of Cabbage Extract
1) Preparation of Heat-Treated Cabbage Extract (HCE)
Cabbage purchased from an agricultural and marine products market was washed, cut to a size of about 0.5 cm χ 0.5 cm χ 0.5 cm, and then freeze-dried. The freeze-dried sample was placed in the inner chamber of a heat-treatment apparatus (Jisco, Seoul, Korea), which was designed and manufactured to be capable of resisting even a pressure of 10 kg/cm2 or higher. Water was placed in the outer chamber, and the sample was heattreated at a temperature of 140 to 150 °C for 6 hours. The apparatus could prevent the sample from coming into direct contact with water and also prevent the carbonization of the sample by direct heat transfer, due to water contained in the outer chamber.
The heat-treated sample was cooled, and then crushed using a crusher, and a 10-fold volume (v/v) of distilled water was added, followed by extraction at 60°C for 2 hours. The extract was filtered, and then freeze-dried before use. The yield of the freeze-dried extract was 1.4% (w/w) relative to the weight of the raw cabbage and 20% (w/w) relative to the weight of the dried cabbage.
2) Preparation of Cabbage Extract (CE)
An extract was prepared in the same manner as described in Example 1, except the heat-treatment process was omitted. The yield of the freeze-dried extract was 1.2% (w/w) relative to the weight of the raw cabbage and 18% (w/w) relative to the weight of the dried cabbage.
Example 2: Evaluation of Cytotoxicity
To measure cytotoxicity, RAW 264.7 cells were dispensed in each well of a 96-well plate at a concentration of 5 χ 103 cells/100 pL. The RAW 264.7 cells were obtained from the Korean Cell Line Bank and cultured with Dulbecco's Modified Eagle's Medium (DMEM) (supplemented with 5% fetal bovine serum (FBS) and 100 iU/mL penicillin and 100 pg/mL streptomycin (P/S)) at 37°C under 5% CO2. Each of the cabbage extract and heat-treated cabbage extract prepared in Example 1 was added to the dispensed cells at a concentration of 125, 250, 500 or 1, 000 pg/ml and incubated for 24 hours, and then the viability of the cells was measured by MTT assay.
FIG. 1 is a graph showing the results of measuring the cell viability. As can be seen therein, both the cabbage extract and the heat-treated cabbage extract showed no cytotoxicity, indicating that these extracts can be used safely.
Example 3: Evaluation of Hepatoprotective Effect of Cabbage Extract
6-8-week-old male BALB/c mice (weighing 19 to 22 g) purchased from Dongyang Biotechnology (Gyeonggi-do, South Korea) were acclimated in a pathogen-free facility under constant condition (temperature: 21 ± 2°C; relative humidity: 60 ± 10%; 12-hr light/12-hr dark cycle) before use. During the experimental period, the animals were allowed to access water and food ad libitum. The animals were divided into the following groups, each consisting of 6 animals: a normal group (untreated group), a negative control group (treated with APAP alone), a positive control group (treated with APAP + NAC), and a sample-administered group (treated with APAP + cabbage extract).
The positive control group was orally administered with NAC, known to have the effect of treating APAP-induced hepatotoxicity, at a daily dose of 75 mg/kg for 7 days, and the sample-administered group was orally administered with 500 mg/kg of the heat-treated cabbage extract, prepared in Example 1, at a daily dose of 500 mg/kg. At 2 hours after the last oral administration of NAC or the sample to the positive control group and the sample-administered group, APAP for inducing hepatotoxicity was intravenously administered to all the groups excluding the normal group at a concentration of 400 mg/kg.
Hours after administration of the sample, blood was collected through the tail vein, and ALT and AST levels in the collected blood were measured by an assay kit (Asan Pharmaceutical) using a substrate-enzyme reaction. FIGS. 2 and 3 show the results of measuring ALT and AST levels, respectively, in the blood. As can be seen therein, the cabbage extract is effective against APAP-induced liver injury. In particular, the cabbage extract had a significant effect against the expression of AST, suggesting that the cabbage extract is more effective against acute liver injury.
After blood collection, the mice were sacrificed, and the liver was dissected out, embedded in paraffin, and then stained with Η & E. FIG. 5 shows staining images of the liver tissue. In FIG. 5, A indicates the normal group; B indicates the negative control group; C indicates the positive control group; and D indicates the sample-administered group. As can be seen in FIG. 5, serious hepatocyte injury induced by APAP was observed, but this injury was significantly healed by NAG or the cabbage extract.
Example 4: Evaluation of Anti-Inflammatory Effect of Cabbage Extract
Since liver injury generally causes acute inflammation, whether the cabbage extract would have an anti-inflammatory
2019204739 02 Jul 2019 effect was examined. To this end, RAW 2 64.7 cells were dispensed in each well of a 6-well plate at a concentration of 5 x 105 cells/100 pL, and then treated with 0.1 pg/ml of LPS. At 30 minutes after LPS treatment, the cells were treated with
1 mg/ml of the cabbage extract (CE) or the heat-treated cabbage extract (HCE) and incubated for 18 hours. Next, RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer's manual. Thereafter, the expression levels of proinflammatory mediators and cytokines were measured by qRT10 PCR using the primers shown in Table 1 below. The results of the measurement are shown in FIG. 5.
Table 1
| Gene | Primer sequence | |
| GAPDH | F: S'-CACTCACGGCAAATTCAACGGCAC-y R: S'-GACTCCACGACATACTCAGCAC-3' | SEQ ID NO:1 SEQ ID NO:2 |
| iNOS | F: 5'-CCCTTCCGAAGTTTCTGGCAGCAGC-3' R: 5'-GGCTGTCAGAGCCTCGTGGCTTTGG-3' | SEQ ID NO:3 SEQ ID NO:4 |
| COX-2 | F: 5'-CACTACATCCTGACCCACTT-3’ R: S'-ATGCTCCTGCTTGAGTATGT-3' | SEQ ID NO:5 SEQ ID NO:6 |
| TNF-a | F: 5'-TTGACCTCAGCGCTGAGTTG-3' R: S'-CCTGTAGCCCACGTCGTAGC-3' | SEQ ID NO:7 SEQ ID NO:8 |
| IL-Ιβ | F: S'-CTGTGGAGAAGCTGTGGCAG-S’ R: S'-GGGATCCACACTCTCCAGCT-3’ | SEQ ID NO:9 SEQ ID ΝΟ.Ί0 |
| IL-6 | F: S’-GTACTCCAGAAGACCAGAGG-3' R: 5'-TGCTGGTGACAACCACGGCC-3* | SEQ ID NO:11 SEQ ID NO:12 |
As can be seen in FIG. 5, the cabbage extract inhibited the expression of the proinflammatory mediators iNOS and COX-2, which was increased by stimulation with LPS, and the expression 5 inhibitory effect of the heat-treated cabbage extract was better than that of the raw cabbage extract.
As described above, the composition of the present invention is prepared using cabbage that has long been used as a food material, and thus it can be used safely in the human 10 body. In addition, it has excellent effects on liver protection and liver function improvement, and thus may be useful as a pharmaceutical composition for preventing or treating liver disease and as a functional health food composition for protecting liver and improving liver function.
Claims (6)
1. A pharmaceutical composition for preventing or treating liver disease, comprising a cabbage extract as an active ingredient.
2. The pharmaceutical composition of claim 1, wherein the cabbage extract is obtained by extracting cabbage after heat-treating the cabbage at a temperature of 100 to 150°C.
3. The pharmaceutical composition of claim 1 or 2, wherein the liver disease is one or more selected from the group consisting of drug-induced liver disease, alcoholic liver disease, acute hepatitis, and fatty liver.
4. The pharmaceutical composition of claim 1 or 2, wherein the extract is obtained by extraction with water, a Cl to C4 alcohol, or a mixture thereof.
5. A functional health food composition for protecting liver and improving liver function, comprising a cabbage extract as an active ingredient.
6. The functional health food composition of claim 5, wherein the cabbage extract is obtained by extracting cabbage
2019204739 02 Jul 2019 after heat-treating the cabbage at a temperature of 100 to
150°C.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180085951A KR102130766B1 (en) | 2018-07-24 | 2018-07-24 | Hepatoprotective Composition Comprising Cabbage Extract |
| KR10-2018-0085951 | 2018-07-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019204739A1 true AU2019204739A1 (en) | 2020-02-13 |
Family
ID=69400689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019204739A Abandoned AU2019204739A1 (en) | 2018-07-24 | 2019-07-02 | Hepatoprotective Composition Comprising Cabbage Extract |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102130766B1 (en) |
| AU (1) | AU2019204739A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100633851B1 (en) | 2004-04-22 | 2006-10-16 | 학교법인 상지학원 | Composition comprising the extract of heat-treated Allium victorialis L. var. platyphyllum for treating or preventing of liver disease or liver protection |
| KR101106499B1 (en) | 2009-03-24 | 2012-01-20 | 장흥군 | Food composition with hepatoprotective effect containing the peduncle extracts of Hovenia dulcis Thunb |
-
2018
- 2018-07-24 KR KR1020180085951A patent/KR102130766B1/en active IP Right Grant
-
2019
- 2019-07-02 AU AU2019204739A patent/AU2019204739A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200011164A (en) | 2020-02-03 |
| KR102130766B1 (en) | 2020-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7069490B2 (en) | Yuricoma longifolia extract and its use in enhancing and / or stimulating the immune system | |
| KR101074158B1 (en) | Composition comprising polysaccharide extracted from panax ginseng preventing and treating liver diseases | |
| Chaudhari et al. | In vitro anti-diabetic and anti-inflammatory activity of stem bark of Bauhinia purpurea | |
| EP2205255B1 (en) | Herbal compositions and methods for treating hepatitic disorders | |
| Xiao et al. | The effect of boletus polysaccharides on diabetic hepatopathy in rats | |
| ZA200506723B (en) | Composition for treating hepatitis C | |
| Cvjetićanin et al. | Dried leaf extract of Olea europaea ameliorates islet-directed autoimmunity in mice | |
| Isworo | Anti-inflammatory activity of date palm seed by downregulating interleukin-1β, TGF-β, cyclooxygenase-1 and-2: A study among middle age women | |
| US20170368135A1 (en) | Herbal drug composition containing probiotic and optionally prebiotic and/or active pharmaceutical ingredient | |
| MX2007010408A (en) | Compositions comprising actinidia and methods of use thereof. | |
| KR20130019352A (en) | A composition comprising the extract of cudrania tricuspidata trunk as an active ingredient for preventing and treating atopic diseases | |
| KR101916580B1 (en) | Composition for treatment or prevention of liver disease comprising extract of Artemisia capillaris, Sanguisorba officinalis L. and Curcuma longa L. and antiviral agent | |
| KR20090089815A (en) | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising mixture of panax species plant leaf extract and processed panax species plant leaf extract | |
| KR20160108771A (en) | Composition for preventing or treating liver disease comprising sarcodon asparatus extract | |
| KR20040084168A (en) | Use of pinitol or chiro-inositol for preventing or treating liver diseases | |
| AU2019204739A1 (en) | Hepatoprotective Composition Comprising Cabbage Extract | |
| Kim | The Effects of Anti-Inflammatory and Liver Function using Heat-Treated Cabbage | |
| KR102119795B1 (en) | Anti-inflammatory Composition Comprising Broccoli Extract | |
| Dahiru et al. | Anti-diabetic potential of Hyphaene thebaica fruit in streptozotocin-induced diabetic rats. | |
| CN109010524B (en) | Application of n-butanol fraction of herba Violae ethanol extract as medicine for preventing immunological liver injury | |
| Maity et al. | A clinical comparative study to evaluate the efficacy and safety of Liv. 52 DS tablets in Non-Alcoholic Steatohepatitis (NASH) | |
| Nguyen-Le et al. | Astaxanthin prevents hepatosteatosis and hyperlipidemia but not obesity in high-fat diet fed mice. | |
| CN111297887B (en) | Preparation method and application of liver-protecting active component of Yunnan ginseng | |
| Hussein et al. | Therapeutic potential and hepatoprotective activity of proanthocyanidin and clopidogrel in non-alcoholic fatty liver disease-induced rats | |
| KR101327218B1 (en) | A pharmaceutical comprising the extract of Opuntia humifusa for treating or preventing acute pancreatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |